Skip to main content
. Author manuscript; available in PMC: 2024 Jul 9.
Published in final edited form as: Clin Cancer Res. 2023 Nov 14;29(22):4586–4595. doi: 10.1158/1078-0432.CCR-23-1283

Figure 2. Real-world cohort of metastatic urothelial carcinoma patients treatment with erdafitinib.

Figure 2.

(A) Waterfall plot depicting best overall response to erdafitinib therapy as well as pre-treatment FGFR3 alteration status and oncoprint depicting selected genomic co-alterations. (B) Swimmer’s plot displaying time on treatment with erdafitinib (Green bars). Orange bars indicate breaks between the last dose of erdafitinib and progression of disease or last follow-up—such breaks in erdafitinib were generally related to treatment-related toxicities. Black arrows denote patients who remain without progression of disease at last follow-up. Red “x”s denote patient deaths. Blue arrows denote patients who developed second site mutations of FGFR3 detected in cell-free DNA after initiating erdafitinib. (C) Kaplan-Meier analysis of progression-free survival of patients treated with erdafitinib therapy.

CI, confidence interval; PFS, progression-free survival

*FGFR3 alteration detected in pre-treatment cell-free DNA; all other baseline FGFR3 alterations displayed were detected by tumor sequencing.